Nyxoah Appoints John Landry as Chief Financial Officer

Core Insights - Nyxoah has appointed John Landry as Chief Financial Officer, effective November 4, 2024, to enhance its focus on the U.S. market [1][3] - Loïc Moreau, the current CFO, will transition to the newly created role of President International, leading global expansion efforts [3][4] Company Overview - Nyxoah is a medical technology company focused on developing innovative treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation [5] - The company's flagship product, Genio®, is a battery-free hypoglossal neuromodulation device designed for OSA treatment [5] Leadership Experience - John Landry brings over 20 years of financial leadership experience in the healthcare and medtech sectors, previously serving as CFO at Vapotherm Inc., where he contributed to significant revenue growth in the U.S. market [2][3] Strategic Goals - The appointment of John Landry is aimed at optimizing financial strategies and driving operational efficiencies as Nyxoah prepares Genio for commercialization in the U.S. [3] - The company is committed to building a strong leadership team to support its ambitious growth objectives [4] Regulatory Milestones - Genio® received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [6] - Nyxoah has completed two successful IPOs, on Euronext Brussels in September 2020 and NASDAQ in July 2021 [6] - The company has received CE mark approval for expanding therapeutic indications to Complete Concentric Collapse (CCC) patients, which are currently contraindicated in competitors' therapies [6]